Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRB 701 (Primary)
  • Indications Cervical cancer; Head and neck cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals

Most Recent Events

  • 18 Oct 2025 According to a Corbus Pharmaceuticals media release, the company plans to meet with the FDA this year to review the data and expects to initiate registrational studies by mid-2026.
  • 18 Oct 2025 Results (n=167) presented in the Corbus pharmaceuticals media release.
  • 22 Sep 2025 According to a Corbus Pharmaceuticals media release, company will host an in-person and virtual KOL event, will be held at the Berlin Germany Marriott starting at 10AM CEST on Sunday 19 Oct 2025, at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from phase 1/2 clinical study of CRB-701 (SYS6002).Data from over 100 participants with either head and neck squamous cell carcinoma, cervical, or metastatic urothelial tumors will be presented

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top